MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2026.1911781

Медицинская библиотека · Frontiers in immunology · 2026

Optimal timing of surgery after conversion therapy for initially unresectable hepatocellular carcinoma: a multicenter study integrating major pathological response and treatment duration.

Li Siming, Li Minjun, Zhu Fan, Qin Yue, Tang Weiling, Yao JiaWen, Chen Jiahao, Liu Liang, Liang Zhiyin, Wei Huaning, He Yuxia, Wang Guang, Zhang Jie, Xiang Bangde

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVE

The optimal timing of surgery after conversion therapy for initially unresectable hepatocellular carcinoma (uHCC) remains unclear. This study aimed to evaluate whether surgical timing can be optimized by integrating major pathological response (MPR), defined as residual viable tumor (RVT) ≤15%, with preoperative treatment duration.

METHODS

This multicenter retrospective study enrolled patients with initially uHCC who underwent curative-intent hepatectomy after comprehensive conversion therapy at seven tertiary hospitals between January 2020 and December 2025. The prognostic cutoff for MPR was determined using restricted cubic spline (RCS) models. Patients were categorized into three groups according to the interval from initiation of conversion therapy to surgery: <12 weeks, 12-24 weeks, and >24 weeks. MPR rates, survival outcomes, and perioperative safety were compared among the three groups.

RESULTS

A total of 257 patients were included. RCS analysis showed that a higher RVT proportion was associated with increased risks of poor overall survival (OS) and recurrence-free survival (RFS), with the most pronounced change in risk observed at an RVT threshold of 15%. Therefore, RVT ≤15% was defined as MPR in this study. The overall MPR rate was 63.4% (163/257). MPR was an independent protective factor for both OS and RFS. The MPR rate increased progressively with longer treatment duration (41.3% in the <12-week group, 66.2% in the 12-24-week group, and 73.0% in the >24-week group). OS differed significantly among the three duration groups, whereas the difference in RFS was not statistically significant. The incidences of severe postoperative complications and high-grade adverse events were low across all groups and did not increase markedly with prolonged therapy.

CONCLUSIONS

RVT ≤15% may serve as a prognostically meaningful criterion for MPR after conversion therapy for uHCC. To balance the degree of pathological response, long-term survival benefit, and perioperative safety, a treatment-to-surgery interval of 12 to 24 weeks may be optimal.

Для цитирования: Li Siming, Li Minjun, Zhu Fan, Qin Yue, Tang Weiling, Yao JiaWen, Chen Jiahao, Liu Liang, Liang Zhiyin, Wei Huaning, He Yuxia, Wang Guang, Zhang Jie, Xiang Bangde. Optimal timing of surgery after conversion therapy for initially unresectable hepatocellular carcinoma: a multicenter study integrating major pathological response and treatment duration.. Frontiers in immunology. 2026. DOI: 10.3389/fimmu.2026.1911781.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.